Pharmacokinetic/pharmacodynamic analyses
PK samples were taken in Module 1A, Module 1 B-1 and Module 2A (see schedule of assessments in Supplementary Information for timing of PK samples). PK parameters were derived using standard non-compartmental methods.Per-protocol ctDNA samples were taken in Module 1B-1 at screening, C1D1, C2D1 and on D1 of alternating cycles from Cycle 3; in Module 2A at screening, C1D1 and at either C2D1 (240 mg) or C2D15 (360 mg) for mutational analysis